logo-loader
viewSmith & Nephew PLC

Smith & Nephew acquires grommet maker Tusker Medical

Tusker Medical has developed Tula System, a technology that allows children to receive the correct treatment for ear infections without undergoing surgery

Smith & Nephew acquires ear tubes specialist Tusker Medical

Smith & Nephew PLC (LON:SN.) has announced the acquisition of ear tubes specialist Tusker Medical, Inc. for an undisclosed sum.

The FTSE 100-listed firm said it was financed from existing cash and debt facilities.

READ: Smith & Nephew replaces guidance for revenues and profit margins

Tusker Medical’s lead product is Tula System, a technology that allows children to receive treatment for ear infections without undergoing surgery.

Normally, they are given a general anaesthetic, which poses risks and increases the cost but Tula can be administered to children aged over six months in the physician's office.

'Breakthrough device'

Tula System received the ‘breakthrough device’ denomination by the US Food & Drug Administration (FDA), which speeds up approval processes for products providing more effective treatment for life-threatening or debilitating conditions.

In November it received pre-market approval, whereby the FDA deems it safe and effective, paving the way for marketing approval.

“It is a game-changer when treating children, removing the risk and stress of general anaesthesia for patients and caregivers,” said Brad Cannon, president of sports medicine & ear, nose and throat (ENT) at Smith+Nephew, in a release.

“Tula is a highly complementary addition to our ENT portfolio, and we are excited to significantly improve the treatment options for surgeons and patients with the launch of this technology.”

Quick facts: Smith & Nephew PLC

Price: 47.88 USD

NYSE:SNN
Market: NYSE
Market Cap: $20.95 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Genprex sees newly licensed diabetes gene therapy as an...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based biotech has signed a licensing agreement with the University of Pittsburgh for a diabetes gene therapy that could have the potential to treat Type 1 and Type 2 diabetes. Varner says the newly licensed diabetes gene...

2 days, 15 hours ago

2 min read